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One of the most exciting recent discoveries in the field of biology was the demonstration that both 
mouse and human somatic cells engineered via epigenetic reprogramming for the expression of 
combinations of few defined transcription factors (including Oct4, KLF4, Sox2, NANOG, LIN28, and 
c-Myc) can become pluripotent [1–3]. These cells closely resemble embryonic stem (ES) cells for 
their pluripotency and have been defined as induced pluripotent stem (iPS) cells. These cells have 
rapidly emerged as very promising tools for the achievement of significant advancement in 
different fields without the controversies and ethical concerns associated with the use of human 
ES cells [4]. In particular, the possibility to get iPS cells from readily obtainable somatic cells 
theoretically opened the way to a number of perspectives and practical applications, including (1) 
to design and test patient-customized (i.e., autologous) cell therapy without the need for immune 
suppression and (2) to increase our knowledge on mechanisms of inherited diseases with a 
realistic opportunity, as recently shown for human iPS-derived hepatocytes [5–7], for modeling 
inherited metabolic human diseases, understanding disease pathogenesis, and for drug discovery 
and testing. It should be anticipated, however, that the latter objective (i.e., the use of human iPS 
cell-derived hepatocytes for drug discovery and testing) can currently be envisaged as the most 
useful and safe application. Indeed, a number of relevant limitations have progressively emerged 
in relation to the clinical use of iPS cells and different laboratories have developed strategies in 
order to at least partially overcome such limitations. 
The original methods used in order to derive iPS cells from either human or mouse somatic cells 
employed viral vectors, a strategy leading to the integration of both desired transgenes and vector 
backbone into the host cell genome [1–3]. Of relevance, the use of these vectors is at risk to 
produce insertional mutations and genetic alterations able to interfere with normal functions of 
cells derived from iPS cells and to favor reactivation of reprogramming factors at later stages. 
Indeed, residual transgene expression has been reported to affect differentiation into specific 
lineages [2] or even result in tumorigenesis [8–10]. At present, the oncogenic potential of iPS cells 
represents a major concern for clinical application [9] since these cells, much as ES cells, can 
readily form teratomas when injected into immunodeficient mice. This may rely, for both iPS and 
ES cells, on the presence of residual diploid pluripotent cells that have not undergone 
differentiation in the population of transplanted human ES or iPS cells [9]. Moreover, tumor 
formation in iPS cell chimeric mice has been attributed to the expression of c-Myc in iPS cell-
derived somatic cells, irrespective of the type of the original somatic cell employed [9–13]. 
However, as well reviewed [9], several other reasons are likely to underlie iPS cell tumorigenicity. 
In particular, although iPS cells may behave similarly to ES cells, differences between these two 
kinds of cells indeed exist and this is particularly significant for human cells, with human iPS cells 
being more tumorigenic than human ES cells because of genetic and epigenetic causes [9]. 
Along these lines, human iPS cells have been reported to acquire chromosomal alterations and 
genetic changes (including aneuploidy, gain or loss of small chromosomes, and point mutations) 
even more readily than ES cells [9, 14]. Human ES cells, which are derived from the inner mass of 
blastocysts, may acquire chromosomal abnormalities mainly following prolonged growth in 
culture. By contrast, human iPS cells can acquire chromosomal alterations as a result of multiple 
events, including (1) long-term culture of somatic cells of origin, that are more likely to then carry 
genetic abnormalities which may be even selected during reprogramming; (2) the stress 
associated with reprogramming itself; and (3) long-term passaging of iPS cells in culture [9, 14]. 
In addition, increased tumorigenicity of human iPS cells versus ES cells can also depend on 
epigenetic differences. It has been recently proposed that global gene expression patterns 
between these two kinds of cells may differ significantly, although prolonged culture may bring iPS 
and ES cells transcriptionally closer [15–17]. In particular, human iPS cells have been reported to 
overexpress cancer-related miRNAs as well as to carry alterations in cancer-specific gene promoter 
DNA methylation that arise during reprogramming to persist thereafter. Even more interesting, it 
has recently been proposed that both human and mouse iPS cells may retain “epigenetic memory” 
of their cells of origin [18, 19]. Such epigenetic memory may affect tumorigenicity either directly 
as a memory of cellular epigenetic transformation, or indirectly as a memory of epigenetic 
characteristics that make some kind of cells more vulnerable to transformation [9]. This memory 
has been described in a study that analyzed a large-scale methylation profile of several somatic 
donor cells; this study led to the identification of aberrant methylation in a very high number of 
sites, with only some of them being reversed after reprogramming in iPS cells [20]. One should 
also note that some human iPS cells have been reported to show aberrant silencing or activation 
of imprinted genes during the reprogramming process [21], whereas human ES cells usually exhibit 
fairly stable genomic imprinting at early stages [22, 23]. 
Where cell cycle and replicative potential are concerned, two more comments should be added. 
First, human iPS cells have been reported to acquire during reprogramming the distinct cell cycle 
properties of ES cells which allow them to divide independently on exogenous mitogenic signals 
(i.e., abbreviated gap phases, high proportion of cells in the S phase and in the M phase of the 
cycle). However, as recently noted [9], the risk for reactivation of the reprogramming factors 
(particularly c-Myc) and the mentioned risk for acquiring genetic abnormalities during propagation 
of iPS in culture are likely to render human iPS cells more vulnerable to cell cycle aberrations. 
Second, the use of potent oncogenes for somatic cell reprogramming as well as the involvement of 
p53 pathway as a defensive barrier against this process and the mentioned epigenetic memory 
may raise the risk for human iPS cells to lead even to the development of somatic tumors (i.e., 
something which is unlikely to apply for ES cells). 
 
Thus, the first general take-home message is that we are still far from the goal to generate safe 
human iPS-derived cells for clinical applications. This goal, according to what was recently 
proposed, should require terminal differentiation or accurate elimination of residual pluripotent 
stem cells or, alternatively, the effective ability to interfere with tumor progression genes (i.e., to 
prevent tumor formation from residual pluripotent cells) [9]. 
Nonetheless, several alternative approaches have been developed in the recent years that have 
started to overcome some of the problems and limitations of the original protocols for iPS 
induction. Along these lines, the Thomson research group [2] made a relevant contribution by 
creating human iPS cells from postnatal adult foreskin fibroblasts adopting a different approach. 
These authors, by employing a lentiviral system to test candidate stemness-related genes, showed 
that reprogramming somatic cells for the expression of Oct4, Sox2, Nanog, and Lin28 genes was a 
strategy sufficient to obtain human pluripotent stem cells [6]. These cells retained relevant 
characteristics of human ES cells avoiding the oncogenic potential related to c-Myc 
reprogramming [6, 8–10]. More recently, it has been shown that reprogramming of Oct4, Sox2, 
and Klf4 expression was sufficient to obtain iPS cells from both mouse and human somatic cells 
[24]. Although these c-Myc-lacking iPS cells were characterized by a much lower efficiency (i.e., if 
compared to iPS cells obtained by reprogramming c-Myc), mice derived from these cells did not 
develop tumors during the study period [24]. 
Since a major challenge in the field was to design methods involving minimal modification to the 
genome in order to generate iPS cells to be used safely for cell therapy [25], several laboratories 
introduced other alternative procedures. Two different studies have reported protocols for the 
derivation of iPS cells in which the procedure leading to integration of the four reprogramming 
factors, based on the use of plasmids [26] or lentiviruses [27], was followed by removing 
transgene sequences from the host genome by means of Cre/lox-mediated excision. Although this 
procedure resulted in the successful removal of transgene sequences, it apparently (see also 
comments in [28]) left behind residual vector sequences. Another approach was described in the 
study by Woltjen et al. [29] where piggyBac transposons (a system requiring only the inverted 
terminal repeats flanking a transgene and transient expression of the transposase enzyme to 
catalyze insertion or excision events) were employed to obtain vector-free murine iPS cells. This 
approach, although elegant and potentially interesting, has been questioned for two main 
reasons: (1) the lack of a definitive proof for effective removal of vector from these cells and (2) 
the hard and difficult work needed to remove multiple transposons. Along these lines, another 
strategy was employed by the group of Thomson [28]; these authors obtained vector- and 
transgene-free iPS cells from human fibroblasts following a procedure requiring a single 
transfection with oriP/Epstein–Barr nuclear antigen-1 (EBNA1)-based episomal vectors. These 
episomal vectors did not integrate in the genome and were completely removed from iPS cells, 
which being free from vectors and transgenes were reported to behave (proliferation and 
developmental potential) similarly to human ES cells. 
 
A further recent development in iPS cell generation has been the so-called “protein transduction” 
approach, a possible alternative to the nucleic-acid-based one for the reprogramming of somatic 
cells into iPS cells without genetic manipulation [30]. The generation of stable iPS cells from mouse 
fibroblasts has been reported by protein transduction of recombinant reprogramming factors 
Oct4, Sox2, Klf4, and c-Myc (designed as poly-arginine protein transduction domain fused to the C-
terminus of the reprogramming factors). These factors were found to enter target cells, remain 
stable within the cells for ≥48 h, and translocate to the nucleus. Interestingly, the design of the 
protocol required four cycles of exposure of mouse fibroblasts to recombinant factors in a 
medium supplemented with valproic acid (VPA), a histone deacetylase (HDAC) inhibitor that can 
significantly improve reprogramming efficiency [30]. This helps to introduce a related approach, 
still designed to avoid or minimize genetic manipulation, in which small molecules are currently 
investigated and proposed as effective tools to modulate ES-cell fate and reprogramming of 
somatic cells. Since the field is a rapidly expanding one (for a comprehensive review see [31]) here 
is sufficient to say that different laboratories have provided evidence that several small molecules, 
including HDAC inhibitors (trichostatin A, suberoylanilide hydroxyamic acid, VPA, and other drugs 
under development) and DNA-methyltransferase inhibitors (5-azacytidine and RG108) can 
improve mouse and human somatic cell reprogramming [31, 32]. Some of these molecules 
improved derivation of iPS cells from human fibroblasts that were reprogrammed for the 
expression of only two factors (Oct4 and Sox2) [33]. To the list of small molecules able to promote 
somatic reprogramming, one may add in the future a number of agents able to specifically affect 
signal transduction pathways (by targeting MEK, GSK3, PKC, etc.) that at present have been 
employed mostly on ES cells (reviewed in [31]). 
The discovery of iPS cells has made them an attractive cellular source, ethically acceptable and 
potentially unlimited, of human hepatocyte-like cells for the study and treatment of human liver 
diseases. At present, there is an urgent need for generation of iPS cells, as a therapeutic approach 
particularly for end-stage chronic liver diseases (CLDs) that represent a worldwide significant cause 
of morbidity and mortality. Moreover, although orthotopic liver transplantation (OLT) can be 
considered as a reliable and efficient therapeutic approach for acute liver failure (ALF), CLDs, and 
non-metastatic liver cancer, the shortage of organ donors and morbidity related to long-term 
immune-suppression therapy represent real concerns. The use of primary/adult hepatocyte 
theoretically should represent the best choice for clinical applications, and indeed some positive 
results have been reported in the past such as successful transplantation of these cells in human 
patients suffering from either ALF or selected metabolic diseases [34–37]. However, the use of 
primary/adult hepatocytes for clinical applications recognizes a number of limitations: (1) any 
strategy involving direct cell therapy (i.e., transplantation of adult hepatocytes) needs the 
availability of a very high number of cells, which is very difficult to achieve; (2) cultured 
hepatocytes are characterized by a slow growth rate and, most relevant, usually undergo 
significant loss of function and de-differentiation; and (3) similar limitations have been described 
for the use of hepatocytes in order to investigate drug toxicity or for human disease modeling [34–
38]. From an historical point of view, these limitations first led several laboratories to explore 
different cellular sources for their potential to differentiate in vitro into hepatocyte-like cells or to 
be transplanted to achieve liver engraftment and hepatocyte-like differentiation in vivo. Cellular 
sources such as embryonic or fetal hepatocytes, hepatic stem/progenitor cells, and extrahepatic 
stem cells (mostly bone marrow-derived) have been extensively used in the last decade and 
results from these studies have been recently critically reviewed and their major limitations 
(ethical, technical, etc.) emphasized [36, 37, 39–41]. In particular, the use of human ES cells faces 
significant ethical concerns in several countries, although these cells have been shown to 
efficiently differentiate into hepatocytes [42]. Having in mind this scenario, different laboratories 
started to work on iPS cells and, as recently reviewed and discussed [7, 25, 42, 43], succeeded in 
differentiating hepatocyte-like cells from either murine [44, 45] or human [5, 6, 46, 47] iPS cells. 
Where human iPS cells are concerned, differentiation into hepatocyte-like cells has been achieved 
using protocols derived from those originally designed for human ES cells [48–50]; these protocols 
may differ in some details but have a relatively common unifying scheme which involves 3–4 steps 
in order to obtain hepatocyte-like cells. The protocol adopted in a study from the group of Duncan 
[40] may serve as a general reference. These authors employed human normal skin fibroblasts in 
which iPS induction was obtained by engineered expression of Oct4, Sox2, Nanog, and Lin28. iPS 
cells were then submitted to a four step protocol: 
1.iPS cells were first exposed to activin A (100 ng/ml) in RPMI medium containing also B27 
supplements for 5 days, a procedure which efficiently induces differentiation of definitive 
endoderm, as already shown for hESC [51, 52]. 
 2.Hepatic specification was then obtained by exposing the cells for additional 5 days to RPMI/B27 
medium containing bone morphogenetic protein-4 (BMP-4, 20 ng/ml) and fibroblast growth 
factor-2 (FGF-2, 10 ng/ml) at a lower pO2 (4%), which is known to contribute to maintain, through 
interrelated action of hypoxia-inducible factor (HIF)-1 and -2, properties of stem cells [53]. 
3.Proliferation of immature hepatocyte-like cells was achieved by exposing cells to RPMI/B27 
medium containing hepatocyte growth factor (HGF, 20 ng/ml) still at 4% pO2. 
 4.Maturation to hepatocyte-like cells was finally obtained at a 20% pO2 by adding hepatocyte 
culture medium (HCM) containing oncostatin M (OSM, 20 ng/ml) for additional 5 days. 
 At the end of this protocol the reported average number of albumin-positive human iPS-derived 
hepatocytes was 81.0 ± 4.8% [30] and these cells were reported to have a convincing morphology 
(including some bi-nucleated cells) and, most important, to express convincing features of 
hepatocyte differentiation (see following text). 
Although such a general protocol to obtain human iPS-derived hepatocyte-like cells may be in 
principle satisfying and quite simple to use, one may observe that it is potentially expensive since 
it requires the use of several cytokines and, even more relevant, is time-consuming. To obtain 
immature and mature hepatocyte-like cells, the protocol requires ≥15 and 20 days, respectively. 
As far as clinical application such as autologous cell therapy may be envisaged, human patients 
(i.e., particularly those experiencing ALF) may have indeed a limited chance to survive such a 
period of time. 
In the current issue of the journal, Takata and coworkers [54], in a study designed to address the 
previous considerations, describe what is likely to be seen as a promising improvement of the 
original general protocol to obtain hepatocyte like-cells from human iPS cells. Although these 
authors referred to the same general scheme derived from hESC protocols, they succeeded in a 
consistent shortening of the procedure, reducing the use of recombinant cytokines to a minimum. 
The Takata et al. [54] protocol, in particular, still requires the use of a shortened step (3 days 
instead of 5) to obtain definitive endoderm cells by exposing them to RPMI/B27 medium 
containing activin A (100 ng/ml), but significantly omits the 5-days hepatic specification step based 
on the exposure to medium containing BMP-4 and FGF-2. This protocol allowed to obtain 
immature and mature (i.e., after OSM-related maturation step) hepatocyte-like cells within 8 and 
13 days, respectively, instead of 15 and 20 as for the original protocol. Moreover, data provided by 
authors apparently indicate that the shortened and simplified procedure was sufficient to obtain a 
scenario of definitive endodermal cells (as deduced by evaluation of FoxA2 and Sox17) and then of 
hepatocyte-like differentiation. Hepatocyte-like phenotype was ascertained by testing albumin 
secretion, urea formation, glycogen storage, cytochrome P450 3A4 (CYP3A4) activity, and 
hepatocyte nuclear factor 4α (HNF4α) transcription, and found as efficient as the original and 
longer protocol or even superior for certain features. 
Although data from Takata et al. [54] study are in principle of interest, a number of cautionary 
notes should be taken into account. As a first comment, the fact that the cells were showing to 
express some appropriate stage-specific markers and hepatocyte-like functions does not allow to 
definitively establish how the cells at the end of the protocol were really similar to mature primary 
human hepatocytes. Indeed, any study designed to generate hepatocyte-like cells should always 
offer a wide analysis of the acquisition of enzymatic, biochemical, and other protein functions 
typical of mature/adult hepatocytes. This should include other essential features in addition to 
those mentioned, including (see e.g., [5, 6]) the capacity to accumulate lipids and to actively take-
up low-density lipoproteins. An analysis of the activity of different specific cytochrome P450 
isoforms and other enzymes involved in drug disposal as well as of the effective ability to 
metabolize agents or drugs (i.e., to more efficiently test phase I and phase II drug metabolizing 
efficiency) should be provided. This can be accompanied by an analysis of liver-specific mRNA 
transcription after differentiation and compared to undifferentiated iPS cells, as in the Duncan’s 
group study [40], but transcriptome analysis should be envisaged just as an additional approach to 
the phenotypic/functional one. 
Still concerning the efficiency of the protocol, an additional comment should be raised that is 
substantially similar to the one addressed by others [7] when commenting a seminal study 
addressing the use of human iPS-derived hepatocytes for modeling inherited metabolic human 
diseases in cell culture systems [5]. Data from Takata et al. [54] study indicate that at the end of 
their protocol a significant percentage of putative hepatocyte-like cells were still α-fetoprotein 
(AFP) positive, making then uncertain to understand how well the protocol-related differentiation 
process was recapitulating the normal development and function of hepatocytes. Along these 
lines, it should be also of interest to know whether during the in vitro differentiation process iPS 
cells express markers of hepatic progenitor cells (e.g., cytokeratin 7 or 19, HepCAM). 
On the contrary, it is interesting to note that Takata et al. [54] did not find relevant differences in 
hepatocyte-like differentiation when using two different parental iPS cell populations. This is a 
rather critical point that should be further addressed and validated in the future by running in 
parallel this kind of experiments (i.e., differentiation of hepatocyte-like cells) on a more significant 
number of parental iPS cells. This is imperative since it has been reported in the literature that 
variability in response to differentiation toward neuronal or hemopoietic lineages among iPS lines, 
either from the same source or from different sources, may exist [55, 56]. 
A final, but in our view, substantial series of critical issues should be considered. In an ideal study, 
the characterization of hepatocyte-like functions should be always followed by specific and 
carefully designed experimental approaches in order to offer a more definitive validation of the 
reliability of differentiated hepatocyte-like cells according to the specific purpose of the study. As 
an example, if cell therapy is the goal, the study should provide specific in vivo evidence that iPS-
derived hepatocyte-like cells may engraft the liver (see [6] where authors checked this by injecting 
differentiated human cells into the right lateral liver lobe of newborn mice and then carefully 
checked engraftment of these cells) and/or display the ability to safely repopulate damaged liver. 
The study by Takata et al. [54] unfortunately does not provide such in vivo evidence and one 
cannot avoid to note that these authors have reprogrammed human somatic cells using 
lentiviruses in order to transduce a combination of factors which still include c-Myc (at least in 
some cells). Moreover, the authors applied none of those previously mentioned procedures which 
have been developed in order to eventually obtain vector- and transgene-free cells. On the basis 
of what we discussed before (tumorigenicity and other concerns), these are likely to represent 
substantial limitations for a cell therapy application. Indeed, here we come once again to a more 
general critical consideration: at present the use of human iPs-derived hepatocyte-like cells for cell 
therapy and regenerative medicine is still far from being a reliable and safe application whereas, 
based on literature data, the most useful applications for human iPS-derived cells are for disease 
modeling, drug discovery and testing, and toxicological purposes. 
At present, at least to our knowledge, just a single murine study has provided evidence that 
somatic cells from wild-type mice reprogrammed to iPS cells may have the potential to undergo in 
vivo normal ontogenic development into mature hepatocytes in the experimental model of mice 
carrying fumarylacetoacetate hydrolase deficiency (FAH −/− mice) [57]. In that study, wild-type 
murine iPS cells were injected into blastocysts of FAH −/− mice giving rise to a generation of 
chimeric mice in which iPS-derived hepatocytes were able to proliferate (even responding to 
two/third partial hepatectomy) and repopulate the liver rescuing the chimeric mice. However, two 
major comments should be raised on this otherwise elegant study: (1) the FAH −/− mice is a rather 
unique and favorable model in the scenario of regenerative medicine applied to hepatology; 
indeed, most of the studies published in the last decade and referring to either acute or chronic 
conditions of experimental liver injury have reported that engraftment and proliferation of 
hepatocyte-like cells from human ESC and iPS cells (as for most studies employing bone marrow-
derived stem cells) in rodents after transplantation are quite limited and then mostly 
disappointing [reviewed in [37, 39–42]) and (2) even more important, a model in which transfer of 
iPS cells are injected into blastocysts should be considered as mostly irrelevant for regenerative 
medicine where the final goal is to obtain safe and adult/mature hepatocyte-like cells to 
transplant under postnatal settings. 
In our view, an excellent example of a realistic study on the actual possible application of human 
iPS-derived hepatocyte-like cells is the one recently published by Rashid et al. [5] which has 
investigated the potential of these cells to model inborn liver diseases. These authors obtained 
human dermal fibroblasts from patients affected by a number of inherited metabolic disorders, 
including α1-antitrypsin deficiency (AAT), glycogen storage disease type 1a deficiency (GSD1), 
hereditary tyrosinemia type 1, Crigler–Najjar syndrome, and familial hypercholesterolemia (FH). 
They first generated a library of patient-specific human iPS cells to be then differentiated into 
hepatocyte-like cells and then characterized iPS cell-derived hepatocytes from patients affected by 
AAT, GSD1, and FH. As noted by Greenbaum [43], AAT, GSD1, and FH are conditions in which three 
different mechanisms of liver disease are involved: (1) defective protein secretion, (2) deficiency of 
a intracellular enzyme, and (3) lack of a plasma membrane receptor, respectively. This study is 
relevant because iPS cell-derived hepatocytes were reported to exhibit all characteristic 
phenotypic abnormalities found in primary hepatocytes obtained from patients affected by these 
diseases. Moreover, although some limitations still exist, as acknowledged by authors and 
discussed in detail elsewhere [7, 43], such a kind of study can disclose the unique and exciting 
opportunity to test drugs that may be tailored to the single individual. 
As a concluding comment, the study by Takata et al. [54] can be envisaged as one more positive 
technical step designed to accelerate the procedure to obtain iPS cell-derived hepatocytes. 
However, one should be aware that more experimental work is needed to overcome current 
limitations as well as experimental and clinical challenges related to the use of these cells and that 
applications other than cell therapy are at present more realistic. 
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